ZYXI:OTCQB-Zynex Inc (USD)

COMMON STOCK | Medical Distribution | OTCQB - U.S. Registered

Last Closing

USD 8.15

Change

+0.26 (+3.30)%

Market Cap

USD 0.01B

Volume

0.07M

Analyst Target

USD 27.35
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Zynex Inc through its subsidiaries, designs, manufactures and sells U.S. Food and Drug Administration medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
HSIC Henry Schein Inc

+1.37 (+1.96%)

USD 8.92B
PDCO Patterson Companies Inc

N/A

USD 1.93B
AHG Akso Health Group ADR

-0.01 (-1.12%)

USD 0.22B
EDAP EDAP TMS SA

-0.09 (-2.78%)

USD 0.12B
YI 111 Inc

+0.09 (+16.07%)

USD 0.05B
COSM Cosmos Health Inc.

+0.14 (+13.43%)

N/A

ETFs Containing ZYXI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.16% 57% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.16% 57% F 28% F
Trailing 12 Months  
Capital Gain -1.69% 100% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.69% 100% F 43% F
Trailing 5 Years  
Capital Gain -9.44% 67% D+ 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.44% 67% D+ 40% F
Average Annual (5 Year Horizon)  
Capital Gain 2.13% 43% F 48% F
Dividend Return 2.13% 43% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.63% 71% C- 42% F
Risk Adjusted Return 4.89% 43% F 42% F
Market Capitalization 0.01B N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative earnings

The company had negative total earnings in the most recent four quarters.